[go: up one dir, main page]

GT200800042A - Metodo de inhibicion de cinasa de tirosina cinasa 3 similar a fms - Google Patents

Metodo de inhibicion de cinasa de tirosina cinasa 3 similar a fms

Info

Publication number
GT200800042A
GT200800042A GT200800042A GT200800042A GT200800042A GT 200800042 A GT200800042 A GT 200800042A GT 200800042 A GT200800042 A GT 200800042A GT 200800042 A GT200800042 A GT 200800042A GT 200800042 A GT200800042 A GT 200800042A
Authority
GT
Guatemala
Prior art keywords
kinase
fms
inhibition method
cell
tyrosine kinase
Prior art date
Application number
GT200800042A
Other languages
English (en)
Inventor
Shelley K Ballentine
Christian Andrew Baumann
Jinsheng Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200800042A publication Critical patent/GT200800042A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A MÉTODO PARA REDUCIR ACTIVIDAD DE QUINASA DE FLT3 EN UNA CÉLULA QUE COMPRENDE PONER EN CONTACTO LA CÉLULA CON UN COMPUESTO DE FÓRMULA GENERAL I EN LA QUE X,A,R2,W, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON DE UTILIDAD EN TRASTORNOS PROLIFERATIVOS DE CÉLULAS TALES COMO EL CÁNCER. T2008
GT200800042A 2005-10-18 2008-05-18 Metodo de inhibicion de cinasa de tirosina cinasa 3 similar a fms GT200800042A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72768705P 2005-10-18 2005-10-18

Publications (1)

Publication Number Publication Date
GT200800042A true GT200800042A (es) 2008-11-03

Family

ID=37864477

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200800042A GT200800042A (es) 2005-10-18 2008-05-18 Metodo de inhibicion de cinasa de tirosina cinasa 3 similar a fms

Country Status (19)

Country Link
US (1) US7795279B2 (es)
EP (1) EP1951234A2 (es)
JP (2) JP2009511628A (es)
KR (1) KR101443651B1 (es)
CN (1) CN101340909B (es)
AU (1) AU2006304897B2 (es)
BR (1) BRPI0617489A2 (es)
CA (1) CA2626623C (es)
CR (1) CR9984A (es)
EA (1) EA200801118A1 (es)
EC (1) ECSP088387A (es)
GT (1) GT200800042A (es)
IL (1) IL190727A (es)
NO (1) NO20082223L (es)
NZ (1) NZ595182A (es)
SV (1) SV2008002880A (es)
UA (1) UA94719C2 (es)
WO (1) WO2007048088A2 (es)
ZA (1) ZA200804253B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846630B2 (en) * 1996-10-18 2005-01-25 Takara Shuzo Co., Ltd. Nucleic acid encoding receptor type protein kinase
ES2611604T3 (es) * 2004-10-22 2017-05-09 Janssen Pharmaceutica Nv Inhibidores de la c fms quinasa
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
UA94719C2 (ru) * 2005-10-18 2011-06-10 Янссен Фармацевтика Н.В. Применение производного имидазол-2-карбоновой кислоты для лечения или профилактики гематологической злокачественной опухоли
AU2007222982A1 (en) * 2006-03-09 2007-09-13 Pharmacopeia, Inc. 8-Heteroarylpurine Mnk2 inhibitors for treating metabolic disorders
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
WO2007124319A1 (en) 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
EP2397138B1 (en) * 2006-04-20 2013-12-11 Janssen Pharmaceutica NV Aromatic amide derivatives as C-KIT kinase inhibitors
AU2007240437B2 (en) 2006-04-20 2012-12-06 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US9109227B2 (en) 2010-01-05 2015-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
WO2011113041A2 (en) * 2010-03-12 2011-09-15 The Johns Hopkins University Neutralization of flt3 ligand as a leukemia therapy
MX347765B (es) 2011-09-30 2017-05-12 Oncodesign Sa Inhibidores macrociclicos de la quinasa flt3.
EP2882757B1 (en) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
CN104370880A (zh) * 2013-01-24 2015-02-25 韩冰 一类蛋白酶抑制剂及其制备方法和用途
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
SG11201600504TA (en) 2013-07-22 2016-02-26 Actelion Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US10065937B2 (en) * 2014-07-31 2018-09-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) FLT3 receptor antagonists
JP6337218B2 (ja) 2015-01-15 2018-06-06 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｃｘｃｒ３受容体調節剤としてのヒドロキシアルキル−ピペラジン誘導体
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
EP3559006A4 (en) * 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES
KR20200013683A (ko) 2017-05-17 2020-02-07 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 오피오이드에 의한 통증 치료 개선용 ｆｌｔ3 저해제
WO2018217766A1 (en) 2017-05-22 2018-11-29 Whitehead Institute For Biomedical Research Kcc2 expression enhancing compounds and uses thereof
TWI757499B (zh) 2017-06-02 2022-03-11 美商輝瑞大藥廠 對flt3具特異性之抗體及其用途
EP3661499A4 (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. COMBINATIONS OF PD-1 ANTAGONISTS AND BENZO [B]
CA3071538A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. Benzo[b]thiophene sting agonists for cancer treatment
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2193143T3 (es) 1992-03-05 2003-11-01 Univ Texas Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
HK1045700B (zh) 1999-04-28 2007-07-27 德克萨斯大学董事会 用於通过选择性抑制vegf来治疗癌症的组合物和方法
US6852752B2 (en) * 1999-12-17 2005-02-08 Vicuron Pharmaceuticals Inc. Urea compounds, compositions and methods of use and preparation
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0005357D0 (en) * 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
DE60113286T2 (de) 2000-10-17 2006-06-22 Merck & Co., Inc. Oral aktive salze mit tyrosinkinaseaktivität
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
US7101884B2 (en) 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
HU230798B1 (hu) 2001-10-30 2018-06-28 Novartis Ag Staurosporin-származékok mint az FLT3 receptor tirozin-kináz aktivitás inhibitorai
ES2247411T3 (es) 2001-12-27 2006-03-01 Theravance, Inc. Derivados de indolinona utiles como inhibidores de la proteina kinasa.
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
AU2003280599A1 (en) 2002-10-29 2004-05-25 Kirin Beer Kabushiki Kaisha QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
MXPA05004754A (es) 2002-11-13 2005-08-02 Chiron Corp Metodos para tratar cancer y metodos relacionados.
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
AU2003297160A1 (en) 2002-12-18 2004-07-22 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
US7427683B2 (en) 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
US20050113566A1 (en) 2003-04-25 2005-05-26 Player Mark R. Inhibitors of C-FMS kinase
EP1631560A2 (en) * 2003-04-25 2006-03-08 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
ES2611604T3 (es) * 2004-10-22 2017-05-09 Janssen Pharmaceutica Nv Inhibidores de la c fms quinasa
US20060281771A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
UA94719C2 (ru) * 2005-10-18 2011-06-10 Янссен Фармацевтика Н.В. Применение производного имидазол-2-карбоновой кислоты для лечения или профилактики гематологической злокачественной опухоли
AR056763A1 (es) * 2005-11-03 2007-10-24 Vertex Pharma Aminopirimidinas sustituidas con tiazol o pirazol,utiles como agentes anticancer y composiciones farmaceuticas que las contienen.
AU2006315334B2 (en) * 2005-11-16 2011-05-19 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors

Also Published As

Publication number Publication date
CA2626623C (en) 2016-08-30
CR9984A (es) 2008-09-09
ECSP088387A (es) 2008-05-30
KR101443651B1 (ko) 2014-09-23
ZA200804253B (en) 2009-11-25
WO2007048088A3 (en) 2007-06-07
IL190727A (en) 2015-05-31
AU2006304897B2 (en) 2012-07-12
JP2014129407A (ja) 2014-07-10
JP2009511628A (ja) 2009-03-19
US20070149572A1 (en) 2007-06-28
AU2006304897A1 (en) 2007-04-26
NO20082223L (no) 2008-07-02
CN101340909A (zh) 2009-01-07
WO2007048088A2 (en) 2007-04-26
BRPI0617489A2 (pt) 2011-07-26
UA94719C2 (ru) 2011-06-10
CN101340909B (zh) 2012-01-11
US7795279B2 (en) 2010-09-14
IL190727A0 (en) 2008-12-29
SV2008002880A (es) 2010-01-05
CA2626623A1 (en) 2007-04-26
EA200801118A1 (ru) 2008-10-30
NZ595182A (en) 2012-12-21
EP1951234A2 (en) 2008-08-06
KR20080064867A (ko) 2008-07-09

Similar Documents

Publication Publication Date Title
GT200800042A (es) Metodo de inhibicion de cinasa de tirosina cinasa 3 similar a fms
GT200500103A (es) 4-fenilamino-quinazolin-6-il-amidas
GT200800258A (es) Compuestos de pirrolo-pirimidina y sus usos
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
GT200600181A (es) Derivados de amida sustituida y metodos de uso
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
MY146989A (en) Kinase inhibitors
HN2005000212A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
UY32606A (es) Sulfonamidas nematocidas
ATE479687T1 (de) Kinaseinhibitoren
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
CO6602158A2 (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
ECSP11011079A (es) Nuevos compuestos de hidroxiareno.
BR112013021896A2 (pt) inibidores de serina/treonina cinase
GT200500242A (es) Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
GT200700077A (es) Compuestos de 4-metilpiridopirimidinona
GT200300087A (es) 2-(2,6-diclorofenil)-diarilimidazoles
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
GT200600174A (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
ATE547411T1 (de) 3-pyrrolo-cyclohexylen-2-dihydroindolinonderiva e und anwendungen davon
CU23889B1 (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su producción y su uso como agentes antinflamatorios
CR10780A (es) Inhibidores de cinasa
ECSP099070A (es) Bencilaminas, un proceso para su producción y su uso como agentes anti-inflamatorios
ECSP078017A (es) Inhibidores de tirosina quinasa
NI200700311A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de la cinasa de flt-3